

The Immunological Basis for Immunization Series

Module 13: Japanese encephalitis

Immunization, Vaccines and Biologicals



**World Health
Organization**

The Immunological Basis for Immunization Series

Module 13: Japanese encephalitis

Immunization, Vaccines and Biologicals



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

The immunological basis for immunization series: module 13: Japanese encephalitis virus.

(Immunological basis for immunization series ; module 13)

1.Encephalitis virus, Japanese - immunology. 2.Japanese encephalitis vaccines - therapeutic use. 3.Encephalitis, Japanese - immunology. 4.Encephalitis, Japanese - epidemiology. I.World Health Organization. II.Series.

ISBN 978 92 4 159971 9

(NLM classification: WC 542)

© World Health Organization 2010

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

**The Department of Immunization, Vaccines and Biologicals
thanks the donors whose unspecified financial support
has made the production of this document possible.**

This module was produced for Immunization, Vaccines and Biologicals, WHO, by:

Dr Janet Daly, Lecturer in Comparative Virology,
School of Veterinary Medicine and Science,
University of Nottingham, Sutton Bonington Campus,
Sutton Bonington LE12 5RD, UK
e-mail: janet.daly@nottingham.ac.uk

and

Prof Tom Solomon, Chair of Neurological Science,
Director of Institute of Infection and Global Health,
University of Liverpool, L69 3GA, UK
e-mail: tsolomon@liv.ac.uk

Printed in May 2010

**Copies of this publication as well as additional materials
on immunization, vaccines and biological may be requested from:**

World Health Organization
Department of Immunization, Vaccines and Biologicals
CH-1211 Geneva 27, Switzerland
• Fax: + 41 22 791 4227 • Email: vaccines@who.int •

© World Health Organization 2010

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

Printed by the WHO Document Production Services, Geneva, Switzerland

Contents

<i>Abbreviations and acronyms</i>	<i>v</i>
<i>Preface</i>	<i>vii</i>
1. Introduction	1
2. Japanese encephalitis virus structure and replication	3
3. Japanese encephalitis — the disease	5
4. Ecology and epidemiology	6
5. The nature of immunity to Japanese encephalitis	7
5.1 <i>Immunity following natural infection</i>	7
5.2 <i>Vaccine-induced immunity and correlates of protection</i>	8
6. Vaccines	9
6.1 <i>Mouse brain-derived inactivated JE vaccine</i>	9
6.2 <i>Inactivated cell culture-derived vaccines</i>	12
6.3 <i>Live attenuated SA14-14-2 vaccine</i>	13
6.4 <i>Chimeric yellow fever-JE vaccine</i>	17
6.5 <i>Poxvirus-vectored vaccines</i>	17
6.6 <i>DNA vaccine</i>	18
7. Immunization strategies for Japanese encephalitis endemic countries	19
References	21

Abbreviations and acronyms

ADEM	acute disseminated encephalomyelitis
AEFI	adverse events following immunization
C	capsid protein
CDC	Centers for Disease Control and Prevention (USA)
CF	complement fixation
CTL	cytotoxic T lymphocyte
DENV-2	dengue-2 virus
DNA	deoxyribonucleic acid
E	envelope protein
ELISA	enzyme-linked immunosorbent assay
EPI	Expanded Programme on Immunization
GACVS	Global Advisory Committee on Vaccine Safety (WHO)
GIVS	Global Immunization Vision and Strategy
GMT	geometric mean titre
HI	haemagglutination inhibition
IFA	indirect fluorescent antibody test
Ig	immunoglobulin
JE	Japanese encephalitis
JE-CV	chimeric yellow fever–JE (vaccine)
JEV	Japanese encephalitis virus
M	matrix protein
MLD	median lethal dose
MVA	Modified Vaccine Ankara (platform)
MVEV	Murray Valley encephalitis virus
NS	non-structural protein

P3	Peking-3 (strain)
PATH	Program for Appropriate Technology in Health
PHK	primary hamster kidney (cells)
prM	precursor of M protein
PRNT	plaque reduction neutralization test
RNA	ribonucleic acid
SLEV	Saint Louis encephalitis virus
TBEV	tick-borne encephalitis virus
UNICEF	United Nations Children's Fund
USA	United States of America
UTR	untranslated region
WHO	World Health Organization
WNV	West Nile virus
WRAIR	Walter Reed Army Institute of Research

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_29061

